First-In-Human, Phase 1, Randomized, Dose-Escalation Trial with Recombinant Anti–IL-20 Monoclonal Antibody in Patients with Psoriasis

BACKGROUND: The current trial was a first-in-human clinical trial evaluating the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary efficacy of the recombinant monoclonal anti−interleukin-20 (IL-20) antibody, NNC0109-0012, which targets the inflammatory cytokine IL-20. METHODS...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:PLoS One
Auteurs principaux: Gottlieb, Alice B., Krueger, James G., Sandberg Lundblad, Mia, Göthberg, Marie, Skolnick, Brett E.
Format: Artigo
Langue:Inglês
Publié: Public Library of Science 2015
Sujets:
Research Article
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC4529098/
https://ncbi.nlm.nih.gov/pubmed/26252485
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1371/journal.pone.0134703
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires